Breaking Down Star Lake Bioscience Co., Inc.Zhaoqing Guangdong Financial Health: Key Insights for Investors

Investors eyeing Star Lake Bioscience Co., Inc. (600866.SS) will find a mix of scale and improving profitability: H1 2025 operating revenue was 8.16 billion yuan (‑3.85% YoY) with TTM revenue at 17.17 billion yuan and 2024 full-year sales of 17.33 billion yuan; profitability surged-H1 net profit attributable to shareholders rose 65.22% to 836 million yuan, gross margin improved to 20.77% and net margin to 10.28% (+70.95% YoY), supporting a TTM ROE of 15.77% and EPS of 0.77 yuan (P/E ~9.56-10.27); valuation and shareholder returns show a P/S 0.67, market cap near 11-12 billion yuan and a 5.59% dividend yield (0.38 yuan annualized), while leverage sits at a moderate 77.43% debt-to-equity and cash flow per share rose 36.59% YoY to 0.37 yuan-balanced against missing liquidity ratios and debt-detail gaps, raw-material and regulatory risks, and a 450,000-ton amino-acid expansion that could reshape growth prospects, so read on for a deeper breakdown of revenue trends, margins, leverage, valuation multiples and where the key risks and opportunities lie.

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS) - Revenue Analysis

• Top-line trend: modest contraction year-over-year across 2024 and early 2025.
• Productivity: revenue per employee of 1.79 million yuan indicates operational scale given headcount.
• Valuation: P/S of 0.67 implies market is pricing the company below 1x sales.
• Recent growth pressure: quarterly revenue growth at -3.80% signals near-term softness.

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS) - Profitability Metrics

Key profitability figures for Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS) highlight strong margin expansion, solid returns on equity, and shareholder returns in the first half of 2025 and on a trailing twelve months (TTM) basis.

• Net profit attributable to shareholders (H1 2025): ¥836 million (YoY +65.22%).
• Gross profit margin (H1 2025): 20.77% (YoY +31.10%).
• Net profit margin (H1 2025): 10.28% (YoY +70.95%).
• Operating margin (TTM): 15.19%.
• Return on equity (TTM ROE): 15.77%.
• Earnings per share (TTM EPS): ¥0.77; Price-to-earnings (P/E): 9.56.
• Dividend yield: 5.59%; Annualized payout per share: ¥0.38.

• Margin improvements indicate better cost control and/or higher-margin revenue mix supporting the 65%+ net profit growth in H1 2025.
• ROE of 15.77% and an operating margin above 15% point to efficient use of equity and core operations profitability.
• EPS of ¥0.77 with a P/E of 9.56 suggests valuation headroom relative to earnings; the 5.59% dividend yield and ¥0.38 annualized payout demonstrate shareholder return focus.

Further corporate positioning and strategic context can be referenced here: Mission Statement, Vision, & Core Values (2026) of Star Lake Bioscience Co., Inc.Zhaoqing Guangdong.

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS) - Debt vs. Equity Structure

Key capital-structure metrics and available indicators for Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS):

• Debt-to-Equity Ratio: 77.43% (moderate financial leverage).
• Trailing Twelve Months Return on Investment (ROI): 15.77% (investment returns metric).
• Total assets, total liabilities, equity ratio, interest coverage, and recent financing activity: not provided in available data.

• Implication: A 77.43% debt-to-equity implies moderate leverage-useful when paired with ROI of 15.77%, but incomplete without absolute asset/liability levels and interest coverage.
• Risk considerations: Missing interest coverage and liability totals hinder assessment of default risk and liquidity strain under stress.
• Analytical next steps: obtain balance-sheet totals, interest expense, maturity profile, and any recent financing transactions to complete a capital-structure assessment.

Further corporate context and guiding principles can be found here: Mission Statement, Vision, & Core Values (2026) of Star Lake Bioscience Co., Inc.Zhaoqing Guangdong.

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS) Liquidity and Solvency

• Cash flow per share: 0.37 yuan
• Operating cash flow per share YoY change: +36.59%
• Current ratio: Not provided
• Quick ratio: Not provided
• Debt-to-assets ratio: Not provided
• Interest coverage ratio: Not provided
• Working capital (current assets - current liabilities): Not provided
• Cash conversion cycle: Not provided

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS) Valuation Analysis

• Valuation stance: Trailing and forward P/E (10.27 / 9.99) imply a stable earnings outlook with a slight market expectation of continued profitability.
• Balance-sheet view: P/B of 1.42 signals investors are paying a premium over book - not excessively high for the sector but notable.
• Enterprise metrics: EV/Revenue 0.73 and EV/EBITDA 4.67 point to an attractive valuation on both revenue and operating earnings bases.
• Market cap context: ~¥11.95B reflects current investor sentiment and size within the biotech/biopharma universe in China.
• Analyst coverage gap: Absence of specified price targets/consensus reduces reliance on sell-side forecasts for valuation perspective.

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS) - Risk Factors

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS) operates in a high-risk, capital-intensive biotech and pharmaceutical environment. Key risk categories that materially affect its financial health, operating performance and investor returns include raw material volatility, competitive pressure, regulatory shifts, macroeconomic and geopolitical shocks, technological displacement and environmental/sustainability pressures.

• Raw material price volatility: Active pharmaceutical ingredients (APIs) and specialty reagents typically account for a high share of production cost. A 10-30% swing in key input prices can compress gross margins materially in a given quarter.
• Intensifying market competition: Public peers and private biotech entrants in China and abroad are expanding product pipelines and manufacturing capacity, putting pressure on pricing and market share.
• Regulatory and compliance risk: Frequent updates to drug approvals, GMP standards and export controls can delay product rollouts and increase compliance costs.
• Macroeconomic and geopolitical impacts: Demand elasticity for certain therapeutic products can fall during economic downturns; supply-chain disruptions (e.g., port delays, export restrictions) can interrupt production.
• Technological displacement: Competing platforms (biologics, novel delivery systems, generics/biobetters) can erode the company's product advantages and shorten product life cycles.
• Environmental and sustainability costs: Stricter emissions, waste treatment and ESG reporting rules may require capital investments and increase operating expenditures.

Quantitative sensitivity examples (illustrative stress scenarios commonly used by analysts):

• Liquidity and leverage considerations: A single large regulatory setback or price war can stress liquidity if the company carries elevated short-term debt or has concentrated receivables. Typical mitigation strategies for companies in this sector include maintaining 6-12 months of operating cash, committed credit lines, and staged capex.
• Customer and product concentration: If a significant portion of revenue (e.g., >25-40%) is concentrated in a few products or institutional customers, loss of contracts or generic entry presents outsized downside risk.
• Currency and cross-border exposure: Export-oriented business models are exposed to RMB/USD swings; odd currency moves can influence reported margins and cash repatriation.

Operational and strategic mitigation levers investors should monitor:

• Diversification of raw material suppliers and hedging programs to reduce cost-pass-through volatility.
• Continued investment in R&D and product differentiation to sustain pricing power and market position.
• Proactive regulatory engagement and increased compliance spend to avoid approval delays and fines.
• Supply-chain redundancy (alternate logistics routes, local sourcing) to limit disruption risk.
• Capital allocation toward energy-efficient and waste-reduction projects to address rising environmental compliance costs and improve ESG scores.

For historical context on the company's foundation, ownership and how it generates revenue, see: Star Lake Bioscience Co., Inc.Zhaoqing Guangdong: History, Ownership, Mission, How It Works & Makes Money

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS) Growth Opportunities

• 450,000-ton project: targeted commissioning timeline of 2025-2026 with estimated total investment of CNY 3.0-3.5 billion, expected to increase annual amino acid output by ~60-80% versus current capacity.
• Export expansion: management targets raising overseas sales from ~18% of revenue to 30%+ within 3 years through entry into ASEAN, Europe, and North America.
• R&D acceleration: planned R&D spend of CNY 100-150 million annually (up from ~CNY 70 million), focused on high-margin pharmaceutical formulations and specialty amino acids.
• Strategic partnerships: active discussions with three contract research/manufacturing organizations (CMOs) and two regional distributors to broaden market access.
• Operational efficiency: anticipated 6-9% improvement in gross margin via process optimization and scale economies once the new plant reaches steady state.

• Commissioning risk and timeline adherence for the 450,000-ton facility - delays or cost overruns could compress near-term returns.
• Regulatory approvals for new pharmaceutical formulations - successful filings in target markets can unlock premium pricing.
• Realization of export contracts and logistics scalability - container and tariff dynamics may affect realized margins.
• Ability to convert R&D pipeline into commercially viable SKUs - partner collaborations and licensing can shorten commercialization cycles.